1. Dienogest reduces endometrioma volume and endometriosis-related pain symptoms
- Author
-
Yilmaz Sahin, Semih Uludag, Ercan Aygen, and Elif Demirtas
- Subjects
Adult ,medicine.medical_specialty ,Visual analogue scale ,Endometriosis ,Urology ,Pelvic Pain ,Contraceptives, Oral, Hormonal ,03 medical and health sciences ,chemistry.chemical_compound ,Endometrium ,0302 clinical medicine ,medicine ,Humans ,Nandrolone ,Prospective Studies ,Adverse effect ,Menstruation Disturbances ,Pain symptoms ,Pain Measurement ,Uterine Diseases ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics and Gynecology ,Organ Size ,medicine.disease ,Treatment Outcome ,Dienogest ,chemistry ,030220 oncology & carcinogenesis ,Female ,business - Abstract
This study aimed to evaluate the efficacy and adverse effects of dienogest for the treatment of endometriomas. Dienogest (2 mg/day) was administered to patients with endometrioma continuously through the 6-month study period. The patients were prospectively examined on the efficacy and side effects at baseline, at third months, and sixth months of the treatment. Twenty-four out of 30 patients were able to complete the study. The mean volume of the endometrioma decreased significantly from 112.63 ± 161.31 cm³ at baseline to 65.47 ± 95.69 cm³ at a 6-month follow-up (-41%) (
- Published
- 2021